Literature DB >> 28499822

Activation of STAT3/HIF-1α/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN.

Safiyeh Aghazadeh1, Razieh Yazdanparast2.   

Abstract

BACKGROUND: Resistance to the HER2-targeted antibody trastuzumab remains to be a major clinical challenge in the treatment of HER2-positive breast cancer. Hyper-activation of STAT3 is proposed to be a predictive biomarker of trastuzumab resistance. However, the precise mechanism(s) remains poorly defined. Evidence is emerging that HIF-1α, a central downstream element of STAT3 pathway, serves a pivotal role in the complex signaling network with subsequent diverse cellular events.
MATERIAL AND METHODS: We have established trastuzumab resistant SKBR3 cells (SKBR3-TR). The cell viability, apoptosis as well as western blot, siRNA transfection and co-immunoprecipitation assays were performed to evaluate the involvement of STAT3/HIF-1α in modulation of trastuzumab resistance.
RESULTS: We found that in SKBR3-TR cells and conditioned medium-treated parental cells, constitutive phosphorylated STAT3 coincided with prominent up-regulation of HIF-1α which was accompanied with PTEN attenuation. Moreover, the inhibition of STAT3 activation by Stattic and/or genetically STAT3 knocking down decreased HIF-1α level in SKBR3-TR cells. Additionally, treatment with Stattic and/or STAT3 siRNA engendered the up-regulation of PTEN protein in STAT3-inhibited resistant cells. Restoration of PTEN was also observed following siRNA-mediated silencing of HIF-1α expression. Moreover, down-regulation of HIF-1α caused a reduction in the HES-1 content. Further study with HES-1 specific siRNA revealed the elevation of PTEN expression in HES-1 knock-down trastuzumab resistant cells.
CONCLUSION: The impairment of STAT3-HIF-1α-HES-1 pathway restored trastuzumab sensitivity through up-regulation of PTEN protein. GENERAL SIGNIFICANCE: These findings highlighted the signal integrator role of HIF-1α in STAT3-mediated trastuzumab resistance induction which would be valuable in designing more efficient chemosensitization strategies.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HIF-1α; PTEN; STAT3; Trastuzumab resistance

Mesh:

Substances:

Year:  2017        PMID: 28499822     DOI: 10.1016/j.bbagen.2017.05.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta Gen Subj        ISSN: 0304-4165            Impact factor:   3.770


  22 in total

1.  LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells.

Authors:  Keshuo Ding; Zhengsheng Wu; Xiaocan Li; Youjing Sheng; Xiaonan Wang; Sheng Tan
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

2.  Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo.

Authors:  Xiaokai Ding; Amanda C Sharko; Martina S J McDermott; Gary P Schools; Alexander Chumanevich; Hao Ji; Jing Li; Li Zhang; Zachary T Mack; Vitali Sikirzhytski; Michael Shtutman; Laura Ivers; Norma O'Donovan; John Crown; Balázs Győrffy; Mengqian Chen; Igor B Roninson; Eugenia V Broude
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-01       Impact factor: 12.779

Review 3.  Recent Advances in Comprehending the Signaling Pathways Involved in the Progression of Breast Cancer.

Authors:  Andrea Nicolini; Paola Ferrari; Lucrezia Diodati; Angelo Carpi
Journal:  Int J Mol Sci       Date:  2017-11-03       Impact factor: 5.923

4.  Transcriptional repression of human epidermal growth factor receptor 2 by ClC-3 Cl- /H+ transporter inhibition in human breast cancer cells.

Authors:  Mayu Fujimoto; Hiroaki Kito; Junko Kajikuri; Susumu Ohya
Journal:  Cancer Sci       Date:  2018-07-28       Impact factor: 6.716

5.  MicroRNA-645 targets urokinase plasminogen activator and decreases the invasive growth of MDA-MB-231 triple-negative breast cancer cells.

Authors:  Du Meng; Ming Lei; Yaxuan Han; Dongli Zhao; Xiaozhi Zhang; Yunyi Yang; Rui Liu
Journal:  Onco Targets Ther       Date:  2018-11-02       Impact factor: 4.147

6.  Anticancer efficiency of cycloartane triterpenoid derivatives isolated from Cimicifuga yunnanensis Hsiao on triple-negative breast cancer cells.

Authors:  Xiao Li; Wei Wang; Yi Fan; Yue Wei; Li-Qin Yu; Ji-Fu Wei; Yi-Fen Wang
Journal:  Cancer Manag Res       Date:  2018-12-06       Impact factor: 3.989

7.  O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes.

Authors:  Anna Barkovskaya; Kotryna Seip; Bylgja Hilmarsdottir; Gunhild M Maelandsmo; Siver A Moestue; Harri M Itkonen
Journal:  Sci Rep       Date:  2019-04-05       Impact factor: 4.379

8.  Identification of Hub Genes and Pathways in a Rat Model of Renal Ischemia-Reperfusion Injury Using Bioinformatics Analysis of the Gene Expression Omnibus (GEO) Dataset and Integration of Gene Expression Profiles.

Authors:  Ao Guo; Weitie Wang; Hongyu Shi; Jiping Wang; Tiecheng Liu
Journal:  Med Sci Monit       Date:  2019-11-08

Review 9.  STAT3, stem cells, cancer stem cells and p63.

Authors:  Michaela Galoczova; Philip Coates; Borivoj Vojtesek
Journal:  Cell Mol Biol Lett       Date:  2018-03-22       Impact factor: 5.787

Review 10.  A STAT3 of Addiction: Adipose Tissue, Adipocytokine Signalling and STAT3 as Mediators of Metabolic Remodelling in the Tumour Microenvironment.

Authors:  Rose Kadye; Mihlali Stoffels; Sidne Fanucci; Siso Mbanxa; Earl Prinsloo
Journal:  Cells       Date:  2020-04-22       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.